Sintanovo, a company of Sun-Novo, has submitted the IND application for the peptide GHSR-1a agonist STC008. This is the second Class 1 new drug candidate , following the first clinical-stage STC007, a peptide KOR agonist for postoperative pain relief . STC008 Growth hormone secretagogue receptor(GHS-R), also known as ghrelin receptor, a class A G protein-coupled receptor (GPCR), plays a diverse role in physiological functions, such as regulating appetite, alcohol intake, adipocyte metabolism, and maintaining glucose balance. GHSR1a, by binding with ghrelin, plays a significant role in stimulating appetite and increasing food intake. The role of GHS-R is thought to be in regulating energy homeostasis and body weight In 2020, anamorelin, a ghrelin receptor agonist, was approved as the world's first drug for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer, or colorectal cancer in Japan. Unlike megestrol or cor
China Biotech XYZ Shares Updates Related to New Drug Development in China